Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.
Eur Rev Med Pharmacol Sci. 2020 May;24(10):5734-5741. doi: 10.26355/eurrev_202005_21365.
Many parallel-group studies of migraine prophylaxis using valproate medications were reported in recent decades. This meta-analysis assessed the efficacy and safety of valproate medications for migraine prophylaxis in adults.
Searches were conducted in five databases: PubMed, Wiley, ScienceDirect, Web of Science, and the Cochrane Library. The data were acquired through December 31, 2018. Two independent authors searched for controlled clinical trials involving the use of valproate medications in migraine prophylaxis. Studies that met the inclusion criteria were assessed, and their methodological quality was examined.
Seven placebo-controlled studies (782 participants) and seven controlled trials against active comparators (554 participants) were included in the final analysis. The active treatment of valproate medications was significantly superior to placebo (OR, 4.02; 95% CI 2.17-7.44; I2 = 66%). Compared with the other active comparators, there were no significant differences between treatments in the proportion of responders.
Valproate medications were more effective than placebo in migraine prevention, with statistically significant differences. Both valproate and the other active comparators were well-tolerated, and no significant difference was noted in efficacy and safety for the prophylaxis of migraine.
近几十年来，已有许多使用丙戊酸盐药物预防偏头痛的平行组研究报告。本荟萃分析评估了丙戊酸盐药物预防成人偏头痛的疗效和安全性。
在五个数据库中进行了检索：PubMed、Wiley、ScienceDirect、Web of Science 和 Cochrane Library。数据获取截至 2018 年 12 月 31 日。两名独立作者搜索了涉及丙戊酸盐药物预防偏头痛的对照临床试验。评估符合纳入标准的研究，并检查其方法学质量。
最终分析纳入了 7 项安慰剂对照研究（782 名参与者）和 7 项对照试验（554 名参与者）。丙戊酸盐药物的积极治疗明显优于安慰剂（OR，4.02；95%CI 2.17-7.44；I2=66%）。与其他活性对照药物相比，治疗组在应答者比例方面没有显著差异。
丙戊酸盐药物在预防偏头痛方面比安慰剂更有效，差异具有统计学意义。丙戊酸盐和其他活性对照药物均具有良好的耐受性，在预防偏头痛方面，疗效和安全性无显著差异。
